Recent discoveries establish an essential role of circadian clocks in AML but not healthy HSCs. We have developed series of novel selective small molecules targeting different proteins in the circadian system and a new computational drug design platform for discovering new ligands. We aim to develop novel therapies for AML by targeting circadian clocks using these combined approaches.
